Aardvark Therapeutics Files Q1 2025 10-Q

Ticker: AARD · Form: 10-Q · Filed: May 14, 2025 · CIK: 1774857

Aardvark Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyAardvark Therapeutics, INC. (AARD)
Form Type10-Q
Filed DateMay 14, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

**Aardvark Therapeutics Q1 2025 10-Q filed. All systems go.**

AI Summary

Aardvark Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's business address is located at 4370 La Jolla Village Drive, Suite 1050, San Diego, CA 92122. The filing indicates that the company is involved in the Pharmaceutical Preparations industry.

Why It Matters

This filing provides investors with an update on Aardvark Therapeutics' financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing with no immediately apparent significant negative events.

Key Players & Entities

FAQ

What is Aardvark Therapeutics, Inc.'s primary industry?

Aardvark Therapeutics, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the period ending March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on 20250514.

What is the company's business address?

The business address is 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA 92122.

What is Aardvark Therapeutics' SEC File Number?

Aardvark Therapeutics' SEC File Number is 001-42513.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Aardvark Therapeutics, Inc. (AARD).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing